Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab or placebo plus docetaxel in metastatic castration-resistant prostate cancer
2019-002030-36Phase 3Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Nivolumab + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Radiographic progression-free survival. Status: unknown.
02
Drugs
nivolumabdocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-002030-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002030-36.